Myricx Bio is a London-based oncology biotech developing a completely new class of payloads for antibody-drug conjugates (ADCs), built on inhibitors of N-myristoyltransferase (NMT). Spun out of Imperial College London and the Francis Crick Institute, the company aims to give ADCs a fresh way to kill cancer cells that resist today's standard payloads. In July 2024 it closed a £90m ($114m) Series A, one of Europe's largest biotech rounds that year, to push its NMTi-ADC pipeline toward clinical trials.
Valerie Mahoney is a Principal at NFX, one of Silicon Valley's leading seed-stage venture capital firms managing ~$1.5B across four funds. A Materials Science engineer from Imperial College London who earned both an MBA and MPP from Stanford as a Knight-Hennessy Scholar, she brings an operator's lens to early-stage investing after stints at Funding Circle (through IPO), SumUp, Tala, and Cash App/Block. At NFX she focuses on AI, fintech, enterprise software, and marketplaces - backing founders at the pre-seed and seed stages where network effects can be built from the ground up.